Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for adults with HLH: gentler treatment combo under study

NCT ID NCT06160791

Recruiting now Disease control Sponsor: Jerry Lee, MD, MSc, MPhil Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 5 times

Summary

This phase 2 trial is testing a combination of ruxolitinib and a reduced-intensity version of the standard HLH-94 regimen (dexamethasone and etoposide) in 36 adults newly diagnosed with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The goal is to see if this approach can control the disease with fewer toxic side effects. Participants will receive treatment for up to 4 weeks, and researchers will measure how many respond to therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ruxolitinib, etoposide, dexamethasone
What this could lead to
If successful, this could offer a less toxic treatment option for adults with HLH, potentially improving outcomes while reducing side effects.
What could go wrong
This is a small, early-phase trial (36 participants) with no control group, so results may not be definitive. The combination may still cause serious side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophagocytic syndrome Lymphohistiocytosis, Hemophagocytic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES

Contacts and locations

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92697, United States

  • University of California, San Diego

    NOT_YET_RECRUITING

    San Diego, California, 92093, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.